Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate

X

Find Radio Compass News for Abiraterone Acetate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 250MG
  • TABLET;ORAL - 500MG

https://www.businesswire.com/news/home/20240701807541/en

BUSINESSWIRE
01 Jul 2024

https://www.fiercepharma.com/pharma/asco-data-detail-verzenios-flop-prostate-cancer-lilly-seeks-redemption-radiotherapy

Angus Liu FIERCE PHARMA
23 May 2024

https://www.fiercepharma.com/pharma/eli-lillys-growth-drivers-verzenio-and-jardiance-suffer-clinical-setbacks-0

Angus Liu FIERCE PHARMA
01 May 2024

https://www.businesswire.com/news/home/20231003205808/en

BUSINESSWIRE
03 Oct 2023

https://www.businesswire.com/news/home/20230824404671/en

BUSINESSWIRE
24 Aug 2023

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration?utm_medium=email&utm_source=govdelivery#:~:text=On%20August%2011%2C%202023%2C%20the,as%20determined%20by%20an%20FDA%2D

FDA
12 Aug 2023

https://www.ema.europa.eu/en/documents/overview/abiraterone-mylan-epar-medicine-overview_en.pdf

EMA
18 Jul 2023

https://www.biospace.com/article/releases/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/

BIOSPACE
14 Jul 2023

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration#:~:text=On%20May%2031%2C%202023%2C%20the,mCRPC)%2C%20as%20determined%20by%20an

FDA
01 Jun 2023

https://www.businesswire.com/news/home/20230601005453/en

BUSINESSWIRE
01 Jun 2023

https://www.business-standard.com/world-news/us-fda-panel-backs-restricted-use-of-astrazeneca-s-prostate-cancer-drug-123050100632_1.html

BUSINESS-STANDARD
02 May 2023

https://www.fiercepharma.com/pharma/astrazeneca-lynparza-combo-fda-advisory-committee-prostate-cancer-vote

Angus Liu FIERCE PHARMA
29 Apr 2023

https://www.businesswire.com/news/home/20230428005574/en

BUSINESSWIRE
28 Apr 2023

https://endpts.com/janssen-gets-priority-review-for-prostate-cancer-combo-immunogen-reports-q1-elahere-sales/

Tyler Patchen ENDPTS
28 Apr 2023

https://www.europeanpharmaceuticalreview.com/news/180797/mhra-approves-prostate-cancer-combination-therapy/

EUROPEAN PHARMACEUTICAL REVIEW
21 Mar 2023

https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html

PRESS RELEASE
17 Feb 2023

https://www.globenewswire.com/news-release/2023/02/16/2609811/0/en/Janssen-Presents-Updated-Data-Demonstrating-Improved-Outcomes-from-the-Use-of-Niraparib-in-Combination-with-Abiraterone-Acetate-Plus-Prednisone-as-a-First-Line-Therapy-in-Patients-.html

GLOBENEWSWIRE
16 Feb 2023

https://www.prnewswire.com/news-releases/tavanta-therapeutics-announces-positive-top-line-results-from-pivotal-phase-3-trial-of-tavt-45-for-the-treatment-of-metastatic-prostate-cancer-301714563.html

PR NEWSWIRE
05 Jan 2023

https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/

PRESS RELEASE
21 Dec 2022

https://www.businesswire.com/news/home/20221221005090/en

BUSINESSWIRE
21 Dec 2022

https://www.fiercepharma.com/pharma/fda-needs-3-more-months-review-astrazeneca-and-mercks-lynparza-first-line-prostate-cancer

Kevin Dunleavy FIERCEPHARMA
16 Dec 2022

http://pharmabiz.com/NewsDetails.aspx?aid=154468&sid=2

PHARMABIZ
15 Nov 2022

https://www.globenewswire.com/news-release/2022/09/10/2513543/0/en/POINT-Biopharma-Provides-Updated-Efficacy-and-Safety-Data-from-the-Lead-In-Cohort-of-the-Phase-3-SPLASH-Trial-in-mCRPC-at-ESMO-Congress-2022.html

GLOBENEWSWIRE
09 Sep 2022